Company intelligence / Profile preview
Acellytron Therapeutics
Hong Kong, Hong Kong SAR, Chinawuxibiologics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Acellytron Therapeutics is developing ACT-001, an allogeneic anti‑BCMA/GPRC5D bispecific CAR-NK cell therapy for relapsed or refractory multiple myeloma. The program is in early clinical development in China; no published efficacy results are available as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- CAR-NK cell therapyCell therapyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
WuXi Biologics/WuXi AppTec group companies provide manufacturing and R&D support
Beyond the preview
Go deeper on Acellytron Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acellytron Therapeutics.